Antengene Corporation Limited (Antengene-B) announced that on 10 September 2026 it granted a total of 11.52 million restricted share units (RSUs) under its 2022 RSU Scheme to 75 eligible participants. The award represents 11.52 million underlying shares with no purchase price payable by grantees; the company’s shares closed at HK$3.45 on the grant date.
Key allocation • Employees: 6.85 million RSUs to 69 staff members • Executive management: Chief Executive Officer Dr Jay Mei received 0.07 million RSUs and Chief Scientific Officer Dr Bing Hou 2.00 million RSUs (of which 1.43 million will be satisfied by existing shares). • Independent non-executive directors: Ms Jing Qian, Mr Sheng Tang and Dr Rafael Fonseca each received 0.20 million RSUs. • Other senior management: 2.00 million RSUs.
Vesting terms The awards vest in four equal tranches of 25% each on the first, second, third and fourth anniversaries of the grant date. No additional performance conditions apply. A clawback mechanism allows the board to forfeit or reclaim vested or unvested RSUs under specified circumstances such as misconduct or breach of covenants.
Regulatory compliance • Grants to executive and independent non-executive directors were approved by the independent non-executive directors, with each respective director abstaining from voting. • Individual grants remain within the 0.1% limit of issued shares over any 12-month period, so no independent shareholders’ approval is required under Listing Rule 17.04. • Awards form part of directors’ remuneration packages and are exempt from related-party approval requirements under Chapter 14A.
Plan capacity Post-grant, 6.75 million shares remain available under the service-provider sub-limit, and 45.12 million shares remain within the overall mandate limit of the combined 2020 Equity Incentive Plan and 2022 RSU Scheme.
Purpose The board’s remuneration committee stated that the RSU issuance aims to recognise contributions, incentivise retention and align participant interests with long-term corporate growth, consistent with market practice and the scheme’s objectives.